Who is Eligible for CAR T-cell Therapy?

Eligibility for CAR T cell therapy depends on several factors, including the type of cancer, the patient’s overall health, and their response to previous treatments. Here’s a detailed breakdown of the typical eligibility criteria:

1. Cancer Type

CAR T-cell therapy is currently approved for certain types of blood cancers, such as:

• B-cell acute lymphoblastic leukemia (B-ALL): Primarily in children and young adults.
• Diffuse large B-cell lymphoma (DLBCL): For adult patients with relapsed or refractory disease.
• Primary mediastinal large B-cell lymphoma (PMBCL).
• Mantle cell lymphoma (MCL).
• Follicular lymphoma (FL): For patients who have not responded to other therapies.
• Multiple myeloma: For patients with relapsed or refractory multiple myeloma after other treatments.

2. Previous Treatment History

Patients typically qualify if:

• Their cancer is relapsed (returns after initial treatment) or refractory (does not respond to standard treatments).
• They have undergone and failed at least two prior lines of therapy, including chemotherapy, targeted therapy, or stem cell transplant.

3. Health Status

Since CAR T-cell therapy can have significant side effects, candidates need to be in relatively good overall health:

• Adequate organ function (heart, liver, and kidney function must meet specific criteria).
• No uncontrolled infections.
• Patients should not have any autoimmune diseases or conditions that could be worsened by immune activation.

4. Age Requirements

CAR T-cell therapy is approved for both pediatric and adult patients, but age limits may vary depending on the specific type of cancer and therapy.

Contact our specialist and find out whether CAR T cell therapy is the right treatment for you.

5. Performance Status

Doctors assess the patient’s performance status, which measures their ability to carry out daily activities. Patients should have a performance score that indicates they can tolerate the treatment and potential side effects.

6. Availability of CAR T-cell Therapy

CAR T-cell therapy is available only at specialized cancer centers with expertise in administering the treatment and managing complications, such as cytokine release syndrome (CRS) and neurotoxicity.

7. Other Considerations

• Patients may need to undergo additional screening tests (imaging, blood tests, and bone marrow biopsy) to confirm eligibility.
• Participation in clinical trials may be an option for patients who do not meet standard eligibility criteria or who have rare types of cancer.